4D Molecular Therapeutics, Inc. (FDMT) Reports In-Line Q1 EPS

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) reported Q1 EPS of ($0.86), in-line with the analyst estimate of ($0.86). Revenue for the quarter came in at $10 thousand versus the consensus estimate of $529.67 thousand.

For earnings history and earnings-related data on 4D Molecular Therapeutics, Inc. (FDMT) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• Flexsteel (FLXS) Tops Q4 EPS by 24c, Beats on Revenue; Offers Q1 Revenue Guidance
• Lockheed Martin wins $153 million in defense contracts